SHAHRIAR JARCHI: Open Payments
NPI 1417008772 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$352 in 12 payments from 9 companies in 2025. Trend: 2023 $427 · 2024 $96 · 2025 $352
Food & beverage: $352
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $63 |
| Lundbeck LLC | 2 | $62 |
| ABBVIE INC. | 2 | $59 |
| MERZ NORTH AMERICA, INC. | 1 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| Lilly USA, LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Noven Therapeutics, LLC | 1 | $24 |
| Exact Sciences Corporation | 1 | $22 |
Products named: REXULTI, UBRELVY, Xeomin, Wegovy, CAPLYTA, Ozempic, MOUNJARO, Xelstrym.
Industry payments across CA — which companies pay providers there.
